In 2018, Migros presented Gowoonsesang as a good fit for its international export and health strategies. Six years later, it agreed to sell the Korean company to L'Oreal as it refocused on its core business. The agreement, announced on 23 December 2024, brought Dr.G, the skincare brand founded by dermatologist Dr. Gun Young Ahn, into the French buyer's plans. Completion followed on 25 March 2025; the rest of Mibelle took a different route, to Spain's Persan.
Dr.G was the part of Migros's beauty business that fitted a branded consumer-goods owner. Its best-known cream already had a place in Korean shopping routines, and its team knew the domestic and export markets. L'Oreal selected Consumer Products as its home, pairing dermatological origins with an accessible offer. For Migros, the same transaction simplified a much wider industrial portfolio. Neither side needed the company to be newly invented: they were changing where an existing business belonged.
L'Oreal recorded an acquisition cost of EUR 420.5 million for Gowoonsesang in its H1 2025 accounts. Dr.G's own 2024 sales were EUR 128.4 million. That established brand was the centrepiece of a company purchase which also included other labels. The price made this a substantial commitment to Korean skincare, following L'Oreal's earlier acquisition of 3CE.
An Export Ambition Gives Way to a Portfolio Sale
Migros's 2018 annual report celebrated Mibelle's purchase of the Seoul company under its August highlights. The Swiss group connected Dr.G's dermocosmetics specialism with Mibelle's international export strategy and its own health strategy. Gowoonsesang was then a way to broaden the organisation's reach. By February 2024, Migros had changed direction and announced plans to sell Mibelle as it concentrated on its core business.
Alantra, the seller's financial adviser, worked on the Korean disposal as part of that wider programme. Managing partner Michael Maag described an international collaboration which identified L'Oreal as the strategic buyer, while negotiations continued for Mibelle. The separate transaction gave the Korean subsidiary its own destination instead of making its future depend on the sale of every remaining activity.
At the December announcement, Migros Industrie head Matthias Wunderlin welcomed L'Oreal's development plans and Asian market experience. The seller described around 200 employees in South Korea and ten in China, with exports to more than ten Asia-Pacific countries and the United States. Those employees would join L'Oreal. The business changing hands already extended beyond its home market.
A Soothing Cream, a Founder and an Existing Team
Ahn founded the Dr.G brand in 2003, five years after the parent company's establishment. L'Oreal singled out R.E.D Blemish Clear Soothing Cream when explaining the purchase. Its interest lay in ingredient-led skincare sold through a mixture of Korean online and physical retailers. The acquirer described Dr.G as consistently among the country's top three mass-market and dermocosmetic skincare brands, citing Kantar Korea's October 2024 research.
Consumer Products president Alexis Perakis-Valat said his division had followed the brand for years. He set out an ambition to accelerate growth both in Korea and abroad, combining accessible pricing with the brand's specialist identity. Ahn endorsed the move as a new stage in bringing his skincare mission to international customers.
March Brings the Separation Into Effect
The December agreement remained subject to regulatory approval and customary conditions. L'Oreal completed the acquisition on 25 March 2025 and began consolidating Gowoonsesang from that date. Its half-year report put the acquisition cost at EUR 420.5 million, with EUR 401.5 million provisionally recorded as goodwill and other intangible assets.
The buyer's later annual accounts reported Dr.G's 2024 sales at EUR 128.4 million. Alongside the headline brand, Gowoonsesang housed vividraw, Lab.it and Heal us. The team and company structure were therefore part of a broader purchase, even though Dr.G supplied its best-known consumer identity.
On 30 April, the remaining Mibelle Group went to Persan. Migros's annual reporting records the two disposals separately and dates both. The sequence explains why Dr.G emerged under a global branded-beauty group while the rest of the former parent took a different industrial path. It was a division of the seller's portfolio between new owners.
Gowoonsesang Cosmetics acquisition cost, H1 2025 financial report, Note 2.1.1.
Source 4A Second Korean Brand Finds Its Place Beside 3CE
Samuel du Retail, president of L'Oreal Korea, framed Dr.G as the group's second Korean brand after 3CE. He emphasised the acquired teams as well as the label, linking the purchase to a deeper role in Korea's beauty industry. That emphasis makes the local organisation part of the expansion plan: L'Oreal was buying people who had built a business, as well as products it could distribute.
By 12 February 2026, L'Oreal's annual results described Dr.G as successfully integrated. Consumer Products' regional-brand commentary also highlighted Mixa's European rollout and 3CE's Southeast Asian expansion. The division grew 3.5% like-for-like and 0.7% reported in 2025. Dr.G had entered an organisation already developing regional brands alongside its largest global names.
The ownership story had moved from Migros's decision to sell, through a completed transfer, to the buyer reporting integration into the intended division. Dr.G's commercial attraction remained recognisable throughout: an established Korean skincare proposition with room for wider distribution. The acquisition changed its owner and its route to expansion, not the need to keep the product clear and affordable for the customer.
DSML research · 8 October 2026 · Revised 31 October 2026



